Mylan's Purchase Of Matrix Will Speed Launch Of ANDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of the Indian drug maker would give Mylan an edge on generic R&D and production costs as well as access to European markets.